Select Equity Group L.P. Sells 22,755 Shares of Certara, Inc. (NASDAQ:CERT)

Select Equity Group L.P. cut its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 11.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 172,488 shares of the company's stock after selling 22,755 shares during the quarter. Select Equity Group L.P. owned 0.11% of Certara worth $1,837,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in CERT. Venturi Wealth Management LLC increased its holdings in Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock valued at $30,000 after purchasing an additional 2,509 shares during the period. Wells Fargo & Company MN grew its position in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares during the period. Johnson Financial Group Inc. acquired a new position in shares of Certara during the 4th quarter valued at $47,000. Blue Trust Inc. boosted its stake in Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after acquiring an additional 822 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd grew its holdings in Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock worth $58,000 after purchasing an additional 3,656 shares during the period. Institutional investors own 73.96% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on CERT shares. William Blair reiterated a "market perform" rating on shares of Certara in a report on Thursday, February 27th. KeyCorp boosted their target price on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 16th. Stephens reissued an "overweight" rating and issued a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. TD Cowen assumed coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Finally, Robert W. Baird increased their price target on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Stock Down 1.1%

Shares of NASDAQ CERT traded down $0.12 during mid-day trading on Friday, hitting $11.36. 326,156 shares of the stock traded hands, compared to its average volume of 1,322,532. The stock has a fifty day moving average price of $11.77 and a 200-day moving average price of $11.76. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The company has a market cap of $1.84 billion, a price-to-earnings ratio of -56.82, a PEG ratio of 9.29 and a beta of 1.57. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $17.76.

Certara (NASDAQ:CERT - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The firm had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company's quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 earnings per share. Research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.